clinical trial · NCT04485546
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Dompé Farmaceutici S.p.A·phase4·completed·n = 37
Neurotrophic Keratitiscenegermin-bkbj
brief summary
This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
started
Sep 9, 2020
primary completion
Sep 30, 2021
completion
Mar 30, 2022
last updated
Nov 17, 2025
detailed description
This is a 8-week, multicenter, open label, prospective study with 24 weeks of follow-up to evaluate safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK)
official title
An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol